Coulon has more than 20 years of sales, marketing and business development experience within the pharmaceutical industry. Although his background includes a broad list of therapeutic specialities, his strength is in ocular drug development.
Coulon has previously worked at Ciba Vision (Novartis), Akorn, Mallinckrodt Pharmaceuticals, Stonebridge Pharma (GSK), Auriga Laboratories and CCG Partners.
PharmOptima appoints business development director
Ophthalmology specialist hires Rick Coulon
You may also like
Research & Development
![Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines]()
Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines
Adragos Pharma Kawagoe KK has announced the signing of an agreement with Towa Pharmaceutical Co., Ltd, to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals
Research & Development
![PharmNovo reports broader therapeutic potential for PN6047]()
PharmNovo reports broader therapeutic potential for PN6047
PharmNovo AB has announced new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality]()
Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality
Shaped by accelerating regulatory support, expanding clinical evidence and growing institutional acceptance, psychedelic medicine is entering a pivotal phase, reports Joel Latham, Chief Executive Officer, President and Director at Incannex Healthcare Inc.
